Skip to main content
SpringerLink
Log in

Scottish Health Secretary directs SMC to be "more flexible"

  • News item
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. This decision is in contrast to the recent final guidance from NICE not recommending the drug because it was not cost effective; see PharmacoEconomics & Outcomes News 688 p11; 801085739

References

  1. Scottish Medicines Consortium. SMC advice: bimatoprost + timolol (Ganfort Unit Dose Preservative Free); botulinum toxin type a (Botox); carglumic acid (Carbaglu); crizotinib (Xalkori); granisetron (Sancuso); nalmefene (Selincro); pertuzumab (Perjeta). Internet Document : 7 Oct 2013. Available from: URL: http://www.scottishmedicines.org.uk

  2. The Scottish Government. Improving access to new medicines. Media Release : 8 Oct 2013. Available from: URL: http://www.news.scotland.gov.uk

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Scottish Health Secretary directs SMC to be "more flexible". PharmacoEcon Outcomes News 689, 11 (2013). https://doi.org/10.1007/s40274-013-0806-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-013-0806-7

Search

Navigation